Arimoclomol Prospective Doubleblind, Randomised, Placebo-controlled Study in Patients Diagnosed With NiemannPick Disease Type C

Trial Profile

Arimoclomol Prospective Doubleblind, Randomised, Placebo-controlled Study in Patients Diagnosed With NiemannPick Disease Type C

Active, no longer recruiting
Phase of Trial: Phase II/III

Latest Information Update: 17 Jul 2018

At a glance

  • Drugs Arimoclomol (Primary)
  • Indications Niemann-Pick disease type C
  • Focus Registrational; Therapeutic Use
  • Sponsors Orphazyme
  • Most Recent Events

    • 29 May 2018 According to an Orphazyme media release, last patient last visit has been accomplished and database lock is expected in Q3 2018.
    • 15 Mar 2018 According to an Orphazyme media release, results form this trial are expected in Q3 2018.
    • 24 Oct 2017 According to an Orphazyme media release, results of this trial expected in Q3 2018. This study, if positive, will form the basis for a single study filing for NiemannPick Disease Type C, as reported in an Orphazyme media release. The company expects to complete this trial by the end of 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top